These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

565 related articles for article (PubMed ID: 33136431)

  • 1. COVID-19 basics and vaccine development with a Canadian perspective.
    Liu M; Chen X
    Can J Microbiol; 2021 Feb; 67(2):112-118. PubMed ID: 33136431
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Frontrunners in the race to develop a SARS-CoV-2 vaccine.
    Russell RL; Pelka P; Mark BL
    Can J Microbiol; 2021 Mar; 67(3):189-212. PubMed ID: 33264067
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [SARS-CoV-2 vaccines].
    Benfield TL; Helweg-Larsen J
    Ugeskr Laeger; 2021 Mar; 183(10):. PubMed ID: 33734065
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Consensus summary report for CEPI/BC March 12-13, 2020 meeting: Assessment of risk of disease enhancement with COVID-19 vaccines.
    Lambert PH; Ambrosino DM; Andersen SR; Baric RS; Black SB; Chen RT; Dekker CL; Didierlaurent AM; Graham BS; Martin SD; Molrine DC; Perlman S; Picard-Fraser PA; Pollard AJ; Qin C; Subbarao K; Cramer JP
    Vaccine; 2020 Jun; 38(31):4783-4791. PubMed ID: 32507409
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Review of Current Vaccine Development Strategies to Prevent Coronavirus Disease 2019 (COVID-19).
    Bennet BM; Wolf J; Laureano R; Sellers RS
    Toxicol Pathol; 2020 Oct; 48(7):800-809. PubMed ID: 32926660
    [TBL] [Abstract][Full Text] [Related]  

  • 6. New vaccine production platforms used in developing SARS-CoV-2 vaccine candidates.
    Ura T; Yamashita A; Mizuki N; Okuda K; Shimada M
    Vaccine; 2021 Jan; 39(2):197-201. PubMed ID: 33279318
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Artificial intelligence predicts the immunogenic landscape of SARS-CoV-2 leading to universal blueprints for vaccine designs.
    Malone B; Simovski B; Moliné C; Cheng J; Gheorghe M; Fontenelle H; Vardaxis I; Tennøe S; Malmberg JA; Stratford R; Clancy T
    Sci Rep; 2020 Dec; 10(1):22375. PubMed ID: 33361777
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The race for a COVID-19 vaccine.
    Lavigne SE
    Can J Dent Hyg; 2020 Oct; 54(3):107-109. PubMed ID: 33240370
    [No Abstract]   [Full Text] [Related]  

  • 9. Immunoinformatic Analysis of SARS-CoV-2 Nucleocapsid Protein and Identification of COVID-19 Vaccine Targets.
    Oliveira SC; de Magalhães MTQ; Homan EJ
    Front Immunol; 2020; 11():587615. PubMed ID: 33193414
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Deciphering Vaccines for COVID-19: where do we stand today?
    Baviskar T; Raut D; Bhatt LK
    Immunopharmacol Immunotoxicol; 2021 Feb; 43(1):8-21. PubMed ID: 33054486
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Development of safe and highly protective live-attenuated SARS-CoV-2 vaccine candidates by genome recoding.
    Trimpert J; Dietert K; Firsching TC; Ebert N; Thi Nhu Thao T; Vladimirova D; Kaufer S; Labroussaa F; Abdelgawad A; Conradie A; Höfler T; Adler JM; Bertzbach LD; Jores J; Gruber AD; Thiel V; Osterrieder N; Kunec D
    Cell Rep; 2021 Aug; 36(5):109493. PubMed ID: 34320400
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A single dose of recombinant VSV-∆G-spike vaccine provides protection against SARS-CoV-2 challenge.
    Yahalom-Ronen Y; Tamir H; Melamed S; Politi B; Shifman O; Achdout H; Vitner EB; Israeli O; Milrot E; Stein D; Cohen-Gihon I; Lazar S; Gutman H; Glinert I; Cherry L; Vagima Y; Lazar S; Weiss S; Ben-Shmuel A; Avraham R; Puni R; Lupu E; Bar-David E; Sittner A; Erez N; Zichel R; Mamroud E; Mazor O; Levy H; Laskar O; Yitzhaki S; Shapira SC; Zvi A; Beth-Din A; Paran N; Israely T
    Nat Commun; 2020 Dec; 11(1):6402. PubMed ID: 33328475
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efforts towards a COVID-19 vaccine.
    Brüssow H
    Environ Microbiol; 2020 Oct; 22(10):4071-4084. PubMed ID: 32893468
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targets and strategies for vaccine development against SARS-CoV-2.
    Malik JA; Mulla AH; Farooqi T; Pottoo FH; Anwar S; Rengasamy KRR
    Biomed Pharmacother; 2021 May; 137():111254. PubMed ID: 33550049
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Multiepitope Subunit Vaccine Design against COVID-19 Based on the Spike Protein of SARS-CoV-2: An
    Dar HA; Waheed Y; Najmi MH; Ismail S; Hetta HF; Ali A; Muhammad K
    J Immunol Res; 2020; 2020():8893483. PubMed ID: 33274246
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Natural and genetically-modified animal models to investigate pulmonary and extrapulmonary manifestations of COVID-19.
    Tiwari S; Goel G; Kumar A
    Int Rev Immunol; 2024; 43(1):13-32. PubMed ID: 35757923
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A vaccine targeting the RBD of the S protein of SARS-CoV-2 induces protective immunity.
    Yang J; Wang W; Chen Z; Lu S; Yang F; Bi Z; Bao L; Mo F; Li X; Huang Y; Hong W; Yang Y; Zhao Y; Ye F; Lin S; Deng W; Chen H; Lei H; Zhang Z; Luo M; Gao H; Zheng Y; Gong Y; Jiang X; Xu Y; Lv Q; Li D; Wang M; Li F; Wang S; Wang G; Yu P; Qu Y; Yang L; Deng H; Tong A; Li J; Wang Z; Yang J; Shen G; Zhao Z; Li Y; Luo J; Liu H; Yu W; Yang M; Xu J; Wang J; Li H; Wang H; Kuang D; Lin P; Hu Z; Guo W; Cheng W; He Y; Song X; Chen C; Xue Z; Yao S; Chen L; Ma X; Chen S; Gou M; Huang W; Wang Y; Fan C; Tian Z; Shi M; Wang FS; Dai L; Wu M; Li G; Wang G; Peng Y; Qian Z; Huang C; Lau JY; Yang Z; Wei Y; Cen X; Peng X; Qin C; Zhang K; Lu G; Wei X
    Nature; 2020 Oct; 586(7830):572-577. PubMed ID: 32726802
    [TBL] [Abstract][Full Text] [Related]  

  • 18. SARS-CoV-2 infection in patients with a normal or abnormal liver.
    Cabibbo G; Rizzo GEM; Stornello C; Craxì A
    J Viral Hepat; 2021 Jan; 28(1):4-11. PubMed ID: 33190321
    [TBL] [Abstract][Full Text] [Related]  

  • 19. COVID-19 vaccine: A recent update in pipeline vaccines, their design and development strategies.
    Rawat K; Kumari P; Saha L
    Eur J Pharmacol; 2021 Feb; 892():173751. PubMed ID: 33245898
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inactivation of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) by gaseous ozone treatment.
    Yano H; Nakano R; Suzuki Y; Nakano A; Kasahara K; Hosoi H
    J Hosp Infect; 2020 Dec; 106(4):837-838. PubMed ID: 33049366
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 29.